Product Description
Mechanisms of Action: ADRB1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Germany | Russia
Approved Indications: None
Known Adverse Events: None
Company: University Medicine Greifswald
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Obesity, Morbid|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MRI-probe drugs | P1 |
Completed |
Other |
2011-07-01 |
|
| Gastric Bypass | P1 |
Completed |
Obesity, Morbid |
2010-03-01 |
|
| ChiCTR-RRC-10000999 | N/A |
Completed |
Healthy Volunteers |
2009-11-30 |